Iobenguane I-131 - Progenics Pharmaceuticals

Drug Profile

Iobenguane I-131 - Progenics Pharmaceuticals

Alternative Names: 131I-iobenguane - Progenics Pharmaceuticals; 131I-MIBG - Progenics Pharmaceuticals; Azedra; I-131 mIBG; Iobenguane I-131; Iodine-123 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131 iobenguane - Progenics Pharmaceuticals; Iodine-131 metaiodobenzylguanidine - Progenics Pharmaceuticals; MIP-120T; Ultratrace I-131-MIBG; Ultratrace iobenguane I 131; Ultratrace MIBG

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer Molecular Insight Pharmaceuticals; Progenics Pharmaceuticals
  • Class Antineoplastics; Iodobenzenes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Electron transport complex I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Neuroendocrine tumours
  • Phase II Neuroblastoma

Most Recent Events

  • 02 Nov 2017 Progenics Pharmaceuticals completes rolling NDA submission for iobenguane I-131 for Neuroendocrine tumours
  • 11 Sep 2017 Efficacy and pharmacodynamics data from a phase II trial in Neuroendocrine disorders released by Progenics Pharmaceuticals
  • 31 Aug 2017 Preregistration for Neuroendocrine tumours (In adolescents, In children, Second-line therapy or greater, In adults) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top